Regulation of osteoclast activity

被引:96
作者
Greenfield, EM
Bi, YM
Miyauchi, A
机构
[1] Case Western Reserve Univ, Dept Orthopaed, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA
[3] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA
[4] Natl Sanatorium Hyogo Chuo Hosp, Sanda, Hyogo 66913, Japan
关键词
osteoclast activity; osteoclast apoptosis; osteoclast differentiation factor/osteoprotegerin ligand (ODF/OPGL);
D O I
10.1016/S0024-3205(99)00156-3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Osteoclasts are the primary cell type responsible for bone resorption. This paper reviews many of the known regulators of osteoclast activity, including hormones, cytokines, ions, and arachidonic acid metabolites. Most of the hormones and cytokines that inhibit osteoclast activity act directly on the osteoclasts. In contrast, most of the hormones and cytokines that stimulate osteoclast activity act indirectly through osteoblasts. Particularly interesting in this regard are agents that directly inhibit activity of highly purified osteoclasts yet stimulate activity of osteoclasts that are co-cultured with osteoblasts. Recent studies have demonstrated that the primary mechanism by which bone resorptive agents stimulate osteoclast activity indirectly is likely to be up-regulation of production of osteoclast differentiation factor/osteoprotegerin ligand (ODF/OPGL) by the osteoblasts. In addition to discussing regulators of osteoclast activity per se, this paper also reviews the role of osteoclast apoptosis to limit the extent of bone resorption.
引用
收藏
页码:1087 / 1102
页数:16
相关论文
共 177 条
[1]  
ABE E, 1988, J BONE MINER RES, V3, P635
[2]   Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy [J].
Akatsu, T ;
Murakami, T ;
Ono, K ;
Nishikawa, M ;
Tsuda, E ;
Mochizuki, SI ;
Fujise, N ;
Higashio, K ;
Motoyoshi, K ;
Yamamoto, M ;
Nagata, N .
BONE, 1998, 23 (06) :495-498
[3]   Osteoclastogenesis inhibitory factor suppresses osteoclast survival by intetfering in the interaction of stromal cells with osteoclast [J].
Akatsu, T ;
Murakami, T ;
Nishikawa, M ;
Ono, K ;
Shinomiya, N ;
Tsuda, E ;
Mochizuki, S ;
Yamaguchi, K ;
Kinosaki, M ;
Higashio, K ;
Yamamoto, M ;
Motoyoshi, K ;
Nagata, N .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 250 (02) :229-234
[4]  
ALHUMIDAN A, 1991, J BONE MINER RES, V6, P3
[5]   Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency [J].
Ammann, P ;
Rizzoli, R ;
Bonjour, JP ;
Bourrin, S ;
Meyer, JM ;
Vassalli, P ;
Garcia, I .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) :1699-1703
[6]   A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function [J].
Anderson, DM ;
Maraskovsky, E ;
Billingsley, WL ;
Dougall, WC ;
Tometsko, ME ;
Roux, ER ;
Teepe, MC ;
DuBose, RF ;
Cosman, D ;
Galibert, L .
NATURE, 1997, 390 (6656) :175-179
[7]  
[Anonymous], ENV SCI POLLUT RES
[8]   INTERLEUKIN-1 RECEPTOR ANTAGONIST [J].
AREND, WP .
ADVANCES IN IMMUNOLOGY, VOL 54, 1993, 54 :167-227
[9]   Modulation of the resorptive activity of rat osteoclasts by small changes in extracellular pH near the physiological range [J].
Arnett, TR ;
Spowage, M .
BONE, 1996, 18 (03) :277-279
[10]  
ARNETT TR, 1990, J BONE MINER RES, V5, P1099